- Home
- CSQ vs ADPT Comparison
CSQ vs ADPT Comparison
Compare CSQ & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- ADPT
- Stock Information
- Founded
- CSQ 2003
- ADPT 2009
- Country
- CSQ United States
- ADPT United States
- Employees
- CSQ N/A
- ADPT N/A
- Industry
- CSQ Finance Companies
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSQ Finance
- ADPT Health Care
- Exchange
- CSQ Nasdaq
- ADPT Nasdaq
- Market Cap
- CSQ 3.1B
- ADPT 2.6B
- IPO Year
- CSQ N/A
- ADPT 2019
- Fundamental
- Price
- CSQ $19.30
- ADPT $17.36
- Analyst Decision
- CSQ
- ADPT Strong Buy
- Analyst Count
- CSQ 0
- ADPT 10
- Target Price
- CSQ N/A
- ADPT $15.10
- AVG Volume (30 Days)
- CSQ 220.3K
- ADPT 1.6M
- Earning Date
- CSQ 01-01-0001
- ADPT 11-05-2025
- Dividend Yield
- CSQ 7.53%
- ADPT N/A
- EPS Growth
- CSQ N/A
- ADPT N/A
- EPS
- CSQ N/A
- ADPT N/A
- Revenue
- CSQ N/A
- ADPT $205,216,000.00
- Revenue This Year
- CSQ N/A
- ADPT $34.41
- Revenue Next Year
- CSQ N/A
- ADPT $14.03
- P/E Ratio
- CSQ N/A
- ADPT N/A
- Revenue Growth
- CSQ N/A
- ADPT 21.60
- 52 Week Low
- CSQ $12.50
- ADPT $4.27
- 52 Week High
- CSQ $16.45
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- CSQ 55.86
- ADPT 63.04
- Support Level
- CSQ $19.14
- ADPT $16.59
- Resistance Level
- CSQ $19.47
- ADPT $17.40
- Average True Range (ATR)
- CSQ 0.23
- ADPT 0.79
- MACD
- CSQ 0.01
- ADPT -0.07
- Stochastic Oscillator
- CSQ 75.71
- ADPT 80.35
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).